{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:33:14Z","timestamp":1791070394348,"version":"4.1.0"},"reference-count":35,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>l-asparaginase (l-Asp) is an effective drug for treatment of children with acute lymphoblastic leukemia (ALL). The effectiveness is generally thought to result from a rapid depletion of asparagine in serum and cells. Asparagine synthetase (AS) opposes the action of l-Asp by resynthesis of asparagine. In vitro, resistance to l-Asp has been associated with up-regulation of AS mRNA expression. We monitored AS mRNA levels in leukemic cells before and during 5 days after intravenous administration of 1000 IU\/m2 pegylated l-asparaginase (PEG-Asp) in a therapeutic window in children with ALL at initial diagnosis. Within 24 hours, AS mRNA levels increased by 3.5-fold and remained stable in the following 4 days. Baseline and l-Asp\u2013induced expression levels of AS did not differ between clinically good, intermediate, and poor responders to PEG-Asp. No significant difference of AS mRNA up-regulation was found between precursor B- and T-ALL or between hyperdiploids, TEL\/AML1 rearranged ALL or absence of genetic abnormalities. In 3 of 12 patients with T-ALL even a slight down-regulation of AS mRNA expression upon l-Asp exposure was found. In conclusion, although l-Asp exposure induces the expression of AS mRNA, the up-regulated gene expression does not correlate with an early clinical poor response to this drug in children with ALL.<\/jats:p>","DOI":"10.1182\/blood-2005-06-2597","type":"journal-article","created":{"date-parts":[[2006,2,24]],"date-time":"2006-02-24T01:59:19Z","timestamp":1140746359000},"page":"4244-4249","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":67,"title":["Up-regulation of asparagine synthetase expression is not linked to the clinical response l-asparaginase in pediatric acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"107","author":[{"given":"Inge M.","family":"Appel","sequence":"first","affiliation":[{"name":"From the Department of Pediatric Oncology\/Hematology, Erasmus MC\/Sophia Children`s Hospital, Erasmus University Medical Center, Rotterdam, The Netherlands; and the Dutch Childhood Oncology Group, The Hague, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique L.","family":"den Boer","sequence":"additional","affiliation":[{"name":"From the Department of Pediatric Oncology\/Hematology, Erasmus MC\/Sophia Children`s Hospital, Erasmus University Medical Center, Rotterdam, The Netherlands; and the Dutch Childhood Oncology Group, The Hague, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jules P. P.","family":"Meijerink","sequence":"additional","affiliation":[{"name":"From the Department of Pediatric Oncology\/Hematology, Erasmus MC\/Sophia Children`s Hospital, Erasmus University Medical Center, Rotterdam, The Netherlands; and the Dutch Childhood Oncology Group, The Hague, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjo J. P.","family":"Veerman","sequence":"additional","affiliation":[{"name":"From the Department of Pediatric Oncology\/Hematology, Erasmus MC\/Sophia Children`s Hospital, Erasmus University Medical Center, Rotterdam, The Netherlands; and the Dutch Childhood Oncology Group, The Hague, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie C. M.","family":"Reniers","sequence":"additional","affiliation":[{"name":"From the Department of Pediatric Oncology\/Hematology, Erasmus MC\/Sophia Children`s Hospital, Erasmus University Medical Center, Rotterdam, The Netherlands; and the Dutch Childhood Oncology Group, The Hague, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Pieters","sequence":"additional","affiliation":[{"name":"From the Department of Pediatric Oncology\/Hematology, Erasmus MC\/Sophia Children`s Hospital, Erasmus University Medical Center, Rotterdam, The Netherlands; and the Dutch Childhood Oncology Group, The Hague, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111712401941500_REF1","doi-asserted-by":"crossref","unstructured":"Capizzi RL, Bertino JR, Skeel RT. L-asparaginase: clinical, biochemical, pharmacological and immunological status. Ann Int Medicine.1971;74: 893-901.","DOI":"10.7326\/0003-4819-74-6-893"},{"key":"2019111712401941500_REF2","unstructured":"Sallan SE, Hitchcock-Bryan S, Gelber R, Cassady JR, Frei ED, Nathan DG. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res.1983;43: 5601-5607."},{"key":"2019111712401941500_REF3","doi-asserted-by":"crossref","unstructured":"Haskell CM, Canellos GP, Leventhal BG, Carbone PP, Block JB. L-asparaginase resistance in human leukemia-asparagine synthetase. Biochemical Pharmacology.1969;18: 2578-2580.","DOI":"10.1016\/0006-2952(69)90375-X"},{"key":"2019111712401941500_REF4","unstructured":"Broome JD. L-asparaginase: discovery and development as a tumor-inhibitory agent. Cancer Treatment Reports.1981;65: 111-114."},{"key":"2019111712401941500_REF5","doi-asserted-by":"crossref","unstructured":"Andrulis IL, Argonza R, Cairney AE. Molecular and genetic characterization of human cell lines resistant to L-asparaginase and albizziin. Somatic Cell Mol Genet.1990;16: 59-65.","DOI":"10.1007\/BF01650480"},{"key":"2019111712401941500_REF6","doi-asserted-by":"crossref","unstructured":"Hutson RG, Kitoh T, Moraga Amador DA, Cosic S, Schuster SM, Kilberg MS. Amino acid control of asparagine synthetase: relation to resistance in human leukemia cells. Am J Physiol.1997;272: 1691-1699.","DOI":"10.1152\/ajpcell.1997.272.5.C1691"},{"key":"2019111712401941500_REF7","doi-asserted-by":"crossref","unstructured":"Aslanian AM, Kilberg MS. Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 leukaemia cells. Biochem J.2001;358: 59-67.","DOI":"10.1042\/bj3580059"},{"key":"2019111712401941500_REF8","doi-asserted-by":"crossref","unstructured":"Stams WAG, den Boer ML, Holleman A, et al. Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1 negative, but not in TEL-AML1 positive pediatric acute lymphoblastic leukemia. Blood.2005;105: 4223-4225.","DOI":"10.1182\/blood-2004-10-3892"},{"key":"2019111712401941500_REF9","doi-asserted-by":"crossref","unstructured":"Stams WA, den Boer ML, Beverloo HB, et al. Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL. Blood.2003;101: 2743-2747.","DOI":"10.1182\/blood-2002-08-2446"},{"key":"2019111712401941500_REF10","doi-asserted-by":"crossref","unstructured":"Veerman AJ, Hahlen K, Kamps WA, et al. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia: results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol.1996;14: 911-918.","DOI":"10.1200\/JCO.1996.14.3.911"},{"key":"2019111712401941500_REF11","doi-asserted-by":"crossref","unstructured":"Asselin BL, Kreissman S, Coppola DJ, et al. Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia. J Ped Hematol\/Oncol.1999;2: 6-12.","DOI":"10.1097\/00043426-199901000-00003"},{"key":"2019111712401941500_REF12","doi-asserted-by":"crossref","unstructured":"Boos J, Weber G, Ahlke E, Schulze-Westhof P, Nowak-Gottl U, Wurthwein G. Monitoring on asparaginase activity and asparaginase levels in children on different asparaginase preparations. Eur J Cancer.1996;32A: 1544-1550.","DOI":"10.1016\/0959-8049(96)00131-1"},{"key":"2019111712401941500_REF13","doi-asserted-by":"crossref","unstructured":"Muller HJ, Loning L, Horn A, et al. Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL\/NHL-BFM 95 protocols. Br J Hematol.2000;110: 379-384.","DOI":"10.1046\/j.1365-2141.2000.02187.x"},{"key":"2019111712401941500_REF14","doi-asserted-by":"crossref","unstructured":"Appel IM, Pinheiro JPV, Boer den ML, et al. Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL. Leukemia.2003;17: 2254-2256.","DOI":"10.1038\/sj.leu.2403143"},{"key":"2019111712401941500_REF15","unstructured":"Yoshimoto T, Nishimura H, Saito Y, et al. Characterization of polyethylene glycol-modified L-asparaginase from Escherichia coli and its application to therapy of leukemia. Jpn J Cancer Res.1986;77: 1264-1270."},{"key":"2019111712401941500_REF16","doi-asserted-by":"crossref","unstructured":"Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia.2000;14: 2205-2222.","DOI":"10.1038\/sj.leu.2401973"},{"key":"2019111712401941500_REF17","doi-asserted-by":"crossref","unstructured":"Kaspers GJ, Veerman AJ, Pieters R, et al. Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay. Br J Cancer.1994;70: 1047-1052.","DOI":"10.1038\/bjc.1994.446"},{"key":"2019111712401941500_REF18","doi-asserted-by":"crossref","unstructured":"Meijerink J, Mandigers C, Loch vd L, Tonissen E, Goodsaid F, Raemakers A. A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. J Mol Diagn.2001;3: 55-61.","DOI":"10.1016\/S1525-1578(10)60652-6"},{"key":"2019111712401941500_REF19","doi-asserted-by":"crossref","unstructured":"Horowitz B, Madras BK, Meister A, Old LJ, Boyse EA, Stockert E. Asparagine synthetase activity of mouse leukemias. Science.1968;160: 533-535.","DOI":"10.1126\/science.160.3827.533"},{"key":"2019111712401941500_REF20","doi-asserted-by":"crossref","unstructured":"Jousse C, Averous J, Bruhat A, Carraro V, Mordier S, Fafournoux P. Amino acids as regulators of gene expression: molecular mechanisms. Biochem Biophys Res Commun.2004;313: 447-452.","DOI":"10.1016\/j.bbrc.2003.07.020"},{"key":"2019111712401941500_REF21","unstructured":"Chakrabarti R, Schuster SM. L-asparaginase: perspectives on the mechanisms of action and resistance. Int J Ped Hem\/Oncol.1997;4: 597-611."},{"key":"2019111712401941500_REF22","doi-asserted-by":"crossref","unstructured":"Irino T, Kitoh T, Koami K, et al. Establishment of real-time polymerase chain reaction method for quantitative analysis of asparagine synthetase expression. J Mol Diagn.2004;6: 217-224.","DOI":"10.1016\/S1525-1578(10)60513-2"},{"key":"2019111712401941500_REF23","doi-asserted-by":"crossref","unstructured":"Aslanian AM, Fletcher BS, Kilberg MS. Asparagine synthetase expression alone is sufficient to induce L-asparaginase resistance in MOLT-4 human leukaemia cells. Biochem J.2001;357: 321-328.","DOI":"10.1042\/bj3570321"},{"key":"2019111712401941500_REF24","doi-asserted-by":"crossref","unstructured":"Wagner A, Boos J. Unphysiological effects contributing to asparaginase toxicity in vitro. Am J Physiol.1998;274: C1185\u20131186.","DOI":"10.1152\/ajpcell.1998.274.4.C1185"},{"key":"2019111712401941500_REF25","doi-asserted-by":"crossref","unstructured":"Pieters R, den Boer ML, Durian M, et al. Relation between age, immunophenotype and in vitro drug resistance in 395 childern with acute lymphoblastic leukemia: implications for treatment of infants. Leukemia.1998;12: 1344-1348.","DOI":"10.1038\/sj.leu.2401129"},{"key":"2019111712401941500_REF26","doi-asserted-by":"crossref","unstructured":"Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med.1998;339: 605-615.","DOI":"10.1056\/NEJM199808273390907"},{"key":"2019111712401941500_REF27","doi-asserted-by":"crossref","unstructured":"Pieters R, den Boer ML. Molecular pharmacodynamics in childhood leukemia. Int J Hematol.2003;78: 402-413.","DOI":"10.1007\/BF02983812"},{"key":"2019111712401941500_REF28","doi-asserted-by":"crossref","unstructured":"Pieters R, Loonen AH, Huismans DR, et al. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood.1990;76: 2327-2336.","DOI":"10.1182\/blood.V76.11.2327.2327"},{"key":"2019111712401941500_REF29","doi-asserted-by":"crossref","unstructured":"McLean TW, Ringold S, Neuberg D, et al. TEL\/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood.1996;88: 4252-4258.","DOI":"10.1182\/blood.V88.11.4252.4252"},{"key":"2019111712401941500_REF30","unstructured":"Ramakers-van Woerden NL, Pieters R, Loonen AH, et al. TEL-AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood.2000; 96: 1094-1099."},{"key":"2019111712401941500_REF31","doi-asserted-by":"crossref","unstructured":"Kaspers GJL, Veerman AJP, Pieters R, et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhod acute lymphoblastic leukemia. Blood.1997;90: 2723-2729.","DOI":"10.1182\/blood.V90.7.2723"},{"key":"2019111712401941500_REF32","doi-asserted-by":"crossref","unstructured":"Barbosa-Tessmann IP, Chen C, Zhong C, et al. Activation of the human asparagine synthetase gene by the amino acid response and the endoplasmic reticulum stress response pathways occurs by common genomic elements. J Biol Chem.2000;275: 26976-26985.","DOI":"10.1074\/jbc.M000004200"},{"key":"2019111712401941500_REF33","doi-asserted-by":"crossref","unstructured":"Iiboshi Y, Papst PJ, Kawasome H, et al. Amino acid-dependent control of p70 s6k. J Biol Chem.1999;274: 1092-1099.","DOI":"10.1074\/jbc.274.2.1092"},{"key":"2019111712401941500_REF34","doi-asserted-by":"crossref","unstructured":"Holleman A, Cheok MH, den Boer ML, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med.2004;351: 533-542.","DOI":"10.1056\/NEJMoa033513"},{"key":"2019111712401941500_REF35","doi-asserted-by":"crossref","unstructured":"Fine BM, Kaspers GJL, Ho Minh, Loonen AH, Boxer LM. A genome-wide view of the in vitro response to L-asparaginase in acute lymphoblastic leukemia. Cancer Res.2005;65: 291-299.","DOI":"10.1158\/0008-5472.291.65.1"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/11\/4244\/1278539\/zh801106004244.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/11\/4244\/1278539\/zh801106004244.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T15:56:22Z","timestamp":1683388582000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/107\/11\/4244\/21973\/Upregulation-of-asparagine-synthetase-expression"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,1]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,6,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-06-2597","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6,1]]}}}